Furthermore, it has been shown that AR-V7 expression in cancer patients treated with Enza or Abi correlates to a significantly lower PSA response, shorter progression-free time, and lower overall survival time compared to patients who do not express AR-V7 [8, 9]. This evidence concerns the gene AR and cancer.